Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: H James Morris who wrote (109050)	9/27/2000 1:02:18 PM
From: Hobie1Kenobe	Read Replies (1) \| Respond to of 164684

HJ - Thank goodness we have these analysts giving us a heads up before something really bad happens ;0) 12:50 ET priceline.com (PCLN) 10 13/16 -7 13/16 (-42%): -- Update -- Lehman the latest of at least four brokers to downgrade stock. Lowers rating to NEUTRAL from OUTPERFORM, noting that company is essentially a travel agency and is subject to the same challenges that this competitive business presents. Believes investors should lighten up on positions even at these levels.

To: H James Morris who wrote (109050)	9/27/2000 1:04:17 PM
From: Danny	Read Replies (4) \| Respond to of 164684

For whatever it's worth, I established a new position with PCLN at 10 9/16 today. I think the street overreacted. Dont see lots of downside risk here.

To: H James Morris who wrote (109050)	9/27/2000 1:24:33 PM
From: Robert Rose	Read Replies (2) \| Respond to of 164684

Hj, I know you like Seattle and San Diego companies. Do you have any opinion on dndn? I started a modest position today at 25. (May have payed too much, but was tired of chasing the stock since 20, and decided that this runup in the face of this declining mkt indicated strength. Personally, I consider it a high risk/high reward investment. The main thing the stock has going for it is ceo Chris Henne from ikos and immunex, and the team of world-class scientists on board. On the other hand, either Peter or Richard on the Biotech Valuation board (I like it) termed the company's goals as "tough science." At any rate, am interested in your thoughts.... Rob